130 related articles for article (PubMed ID: 7963729)
1. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
Kahn JO; Sinangil F; Baenziger J; Murcar N; Wynne D; Coleman RL; Steimer KS; Dekker CL; Chernoff D
J Infect Dis; 1994 Nov; 170(5):1288-91. PubMed ID: 7963729
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
[TBL] [Abstract][Full Text] [Related]
3. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
O'Hagan DT; Ugozzoli M; Barackman J; Singh M; Kazzaz J; Higgins K; Vancott TC; Ott G
Vaccine; 2000 Mar; 18(17):1793-801. PubMed ID: 10699327
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
[TBL] [Abstract][Full Text] [Related]
5. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
[TBL] [Abstract][Full Text] [Related]
6. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein.
Bui T; Dykers T; Hu SL; Faltynek CR; Ho RJ
J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):799-806. PubMed ID: 8021814
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
Barnett SW; Rajasekar S; Legg H; Doe B; Fuller DH; Haynes JR; Walker CM; Steimer KS
Vaccine; 1997 Jun; 15(8):869-73. PubMed ID: 9234536
[TBL] [Abstract][Full Text] [Related]
8. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
VanCott TC; Mascola JR; Loomis-Price LD; Sinangil F; Zitomersky N; McNeil J; Robb ML; Birx DL; Barnett S
J Virol; 1999 Jun; 73(6):4640-50. PubMed ID: 10233923
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.
Verschoor EJ; Mooij P; Oostermeijer H; van der Kolk M; ten Haaft P; Verstrepen B; Sun Y; Morein B; Akerblom L; Fuller DH; Barnett SW; Heeney JL
J Virol; 1999 Apr; 73(4):3292-300. PubMed ID: 10074183
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
Garrett N; Dintwe O; Monaco CL; Jones M; Seaton KE; Church EC; Grunenberg N; Hutter J; deCamp A; Huang Y; Lu H; Mann P; Robinson ST; Heptinstall J; Jensen RL; Pantaleo G; Ding S; Koutsoukos M; Hosseinipour MC; Van Der Meeren O; Gilbert PB; Ferrari G; Andersen-Nissen E; McElrath MJ; Tomaras GD; Gray GE; Corey L; Kublin JG;
J Acquir Immune Defic Syndr; 2024 Aug; 96(4):350-360. PubMed ID: 38916429
[TBL] [Abstract][Full Text] [Related]
11. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine.
Wintsch J; Chaignat CL; Braun DG; Jeannet M; Stalder H; Abrignani S; Montagna D; Clavijo F; Moret P; Dayer JM
J Infect Dis; 1991 Feb; 163(2):219-25. PubMed ID: 1988506
[TBL] [Abstract][Full Text] [Related]
13. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.
Kahn JO; Steimer KS; Baenziger J; Duliege AM; Feinberg M; Elbeik T; Chesney M; Murcar N; Chernoff D; Sinangil F
J Infect Dis; 1995 May; 171(5):1343-7. PubMed ID: 7751714
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.
McFarland EJ; Borkowsky W; Fenton T; Wara D; McNamara J; Samson P; Kang M; Mofenson L; Cunningham C; Duliege AM; Sinangil F; Spector SA; Jimenez E; Bryson Y; Burchett S; Frenkel LM; Yogev R; Gigliotti F; Luzuriaga K; Livingston RA;
J Infect Dis; 2001 Nov; 184(10):1331-5. PubMed ID: 11679925
[TBL] [Abstract][Full Text] [Related]
15. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant.
Keitel W; Couch R; Bond N; Adair S; Van Nest G; Dekker C
Vaccine; 1993; 11(9):909-13. PubMed ID: 8212835
[TBL] [Abstract][Full Text] [Related]
16. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.
Dey AK; Burke B; Sun Y; Hartog K; Heeney JL; Montefiori D; Srivastava IK; Barnett SW
Vaccine; 2012 Apr; 30(17):2749-59. PubMed ID: 22366638
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
[TBL] [Abstract][Full Text] [Related]
18. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
[TBL] [Abstract][Full Text] [Related]
19. Immune responses induced by prototype vaccines for AIDS in rhesus monkeys.
Ohkawa S; Wilson LA; Larosa G; Javaherian K; Martin LN; Murphey-Corb M
AIDS Res Hum Retroviruses; 1994 Jan; 10(1):27-38. PubMed ID: 8179961
[TBL] [Abstract][Full Text] [Related]
20. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.
Cunningham CK; Wara DW; Kang M; Fenton T; Hawkins E; McNamara J; Mofenson L; Duliege AM; Francis D; McFarland EJ; Borkowsky W;
Clin Infect Dis; 2001 Mar; 32(5):801-7. PubMed ID: 11229849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
